[시장보고서]세계의 안구건조증 치료 시장 - 산업 규모, 점유율, 동향, 기회, 예측 : 적응증별, 제품 유형별, 제형별, 유형별, 유통 채널별, 지역별 경쟁(2020-2030년)

세계의 안구건조증 치료 시장 - 산업 규모, 점유율, 동향, 기회, 예측 : 적응증별, 제품 유형별, 제형별, 유형별, 유통 채널별, 지역별 경쟁(2020-2030년)

Dry Eye Syndrome Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented by Indication, By Product Type, By Dosage Form, By Type, By Distribution Channel, By Region, and Competition, 2020-2030F

상품코드 : 1738276

리서치사 : TechSci Research

발행일 : 2025년 05월

페이지 정보 : 영문 185 Pages

라이선스 & 가격 (부가세 별도)

US $ 4,500

￦ 6,541,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 5,500

￦ 7,995,000

PDF and Excel (Multi-User License)

PDF 및 Excel 보고서를 기업의 팀이나 기관에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다.

US $ 8,000

￦ 11,629,000

PDF and Excel (Custom Research License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다. 80시간의 애널리스트 타임이 포함되어 있고 Copy & Paste 가능한 PPT 버전도 제공됩니다. 짧은 Bespoke 리서치 프로젝트 수행에 맞는 라이선스입니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

세계의 안구건조증 치료 시장은 2024년에는 63억 1,000만 달러로 평가되었으며, 2030년에는 91억 5,000만 달러에 이르고, 예측 기간 동안 CAGR은 6.39%를 나타낼 것으로 전망됩니다.

이 성장을 견인하고 있는 것은 류마티스 관절염, 루푸스, 갑상선 질환 등의 자가면역 질환과 관련된 안구건조증 증상의 유병률 증가입니다. 눈물의 분비를 촉진하는 비강 내 눈물 신경 자극 장치 등의 기술 진보도 수요를 촉진하고 있습니다. 또한 신규 참가 기업 증가에 의해 규제 당국의 승인이 가속해, 치료에의 액세스가 퍼지고 있습니다.

시장 개요
예측 기간	2026-2030
시장 규모 : 2024년	63억 1,000만 달러
시장 규모 : 2030년	91억 5,000만 달러
CAGR : 2025-2030년	6.39%
급성장 부문	수분 부족 안구건조증
최대 시장	북미

시장 성장 촉진요인

노인 인구 증가와 노화에 따른 안 질환

주요 시장 과제

낮은 환자 의식과 과소 진단

주요 시장 동향

인공지능과 진단기술의 통합

시장 규모 및 예측
- 금액별
시장 점유율 및 예측
- 적응증별(증발성 안구건조증, 수분 부족성 안구건조증)
- 제품 유형별(사이클로스포린, 국소 코르티코스테로이드, 인공눈물, 누공 플러그, 기타)
- 제형별(겔, 점안액, 캡슐 및 정제, 점안약, 연고)
- 유형별(처방약, 시판약)
- 유통 채널별(병원 약국, 소매 약국, 온라인 약국)
- 지역별
- 기업별(2024년)
시장 맵
- 적응증별
- 제품 유형별
- 제형별
- 유형별
- 유통 채널별
- 지역별

제7장 북미의 안구건조증 치료 시장 전망

시장 규모 및 예측
시장 점유율 및 예측
북미 : 국가별 분석
- 미국
- 캐나다
- 멕시코

제8장 유럽의 안구건조증 치료 시장 전망

시장 규모 및 예측
시장 점유율 및 예측
유럽 : 국가별 분석
- 프랑스
- 독일
- 영국
- 이탈리아
- 스페인

제9장 아시아태평양의 안구건조증 치료 시장 전망

시장 규모 및 예측
시장 점유율 및 예측
아시아태평양 : 국가별 분석
- 중국
- 인도
- 일본
- 한국
- 호주

제10장 남미의 안구건조증 치료 시장 전망

시장 규모 및 예측
시장 점유율 및 예측
남미 : 국가별 분석
- 브라질
- 아르헨티나
- 콜롬비아

제11장 중동 및 아프리카의 안구건조증 치료 시장 전망

시장 규모 및 예측
시장 점유율 및 예측
중동 및 아프리카 : 국가별 분석
- 남아프리카
- 사우디아라비아
- 아랍에미리트(UAE)

제12장 시장 역학

성장 촉진요인
과제

제13장 시장 동향과 발전

최근 동향
합병과 인수
제품 출시

제14장 세계의 안구건조증 치료 시장 : SWOT 분석

제15장 Porter's Five Forces 분석

업계 내 경쟁
신규 진입의 가능성
공급자의 협상력
고객의 협상력
대체품의 위협/서비스

제16장 경쟁 구도

Johnson & Johnson Services, Inc.
AbbVie Inc.
Bausch Health Companies Inc.
Novartis AG
Sun Pharmaceuticals Industries Limited
Santen Pharmaceutical Co., Ltd.
Otsuka Pharmaceutical Co., Ltd.
Oyster Point Pharma, Inc.
Alcon Inc.
GlaxoSmithKline plc

제17장 전략적 제안

제18장 기업 소개와 면책사항

KTH

영문 목차

영문목차

The Global Dry Eye Syndrome Treatment Market was valued at USD 6.31 billion in 2024 and is projected to reach USD 9.15 billion by 2030, growing at a CAGR of 6.39% during the forecast period. This growth is driven by the increasing prevalence of dry eye conditions linked to autoimmune diseases such as rheumatoid arthritis, lupus, and thyroid disorders. Rising approvals of innovative drug therapies and eye drop formulations, coupled with advancements in R&D for dry eye management, are propelling market expansion. Technological progress, such as intranasal tear neurostimulation devices that promote tear production, is also fostering demand. Additionally, a growing influx of new market entrants is accelerating regulatory approvals and broadening treatment accessibility. However, limited public awareness and underdiagnosis remain significant hurdles for market penetration.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 6.31 Billion
Market Size 2030	USD 9.15 Billion
CAGR 2025-2030	6.39%
Fastest Growing Segment	Aqueous Deficient Dry Eye Syndrome
Largest Market	North America

Key Market Drivers

Rising Geriatric Population and Age-Related Ocular Conditions

The expanding elderly demographic is a key driver for the global dry eye syndrome treatment market, as aging is closely linked to reduced tear production and gland function. Data from the United Nations Department of Economic and Social Affairs indicates that the global population aged 65 and over will exceed 1.6 billion by 2050. Older individuals are more susceptible to dry eye symptoms due to age-related degradation of tear film and meibomian gland health. In the United States, nearly 15% of adults over 50 report symptoms of dry eye, particularly among women. This demographic trend is creating sustained demand for targeted dry eye treatments, especially in developed regions where aging populations are most pronounced.

Key Market Challenges

Low Patient Awareness and Underdiagnosis

Despite its growing prevalence, dry eye syndrome remains significantly underdiagnosed due to limited public awareness and misconceptions about symptoms. Many individuals attribute discomfort to temporary factors and delay seeking professional care, leading to untreated cases. According to the U.S. National Eye Institute, a majority of dry eye sufferers remain undiagnosed, particularly in lower-income regions with limited access to specialized care. Additionally, inconsistent diagnostic standards and limited practitioner training contribute to misclassification and reliance on over-the-counter products. Cultural attitudes and the low prioritization of eye health in some countries further exacerbate this issue, restricting treatment adoption and hindering market growth.

Key Market Trends

Integration of Artificial Intelligence and Diagnostic Technologies

Artificial intelligence and advanced diagnostic tools are transforming how dry eye syndrome is detected and managed. AI-based imaging systems are increasingly used to assess tear stability, gland function, and ocular surface conditions with higher accuracy than manual observation. These tools are essential in streamlining diagnostics, particularly in teleophthalmology and high-volume clinical settings. Regulatory and funding support, such as the FDA's approval of AI diagnostic tools and the NIH's investments in healthcare AI, are accelerating adoption. Countries like Japan and South Korea are implementing AI within smart hospitals to enhance diagnostic efficiency. This technological integration supports early intervention, improves treatment outcomes, and lowers long-term healthcare expenditures related to untreated dry eye.

Key Market Players

Johnson & Johnson Services, Inc.
AbbVie Inc.
Bausch Health Companies Inc.
Novartis AG
Sun Pharmaceuticals Industries Limited
Santen Pharmaceutical Co., Ltd.
Otsuka Pharmaceutical Co., Ltd.
Oyster Point Pharma, Inc.
Alcon Inc.
GlaxoSmithKline plc

Report Scope:

In this report, the Global Dry Eye Syndrome Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Dry Eye Syndrome Treatment Market, By Indication:

Evaporative Dry Eye Syndrome
Aqueous Deficient Dry Eye Syndrome

Dry Eye Syndrome Treatment Market, By Product Type:

Cyclosporine
Topical Corticosteroids
Artificial Tears
Punctal Plugs
Others

Dry Eye Syndrome Treatment Market, By Dosage Form:

Gels
Eye Solutions
Capsules & Tablets
Eye Drops
Ointments

Dry Eye Syndrome Treatment Market, By Type:

Prescription
Over The Counter

Dry Eye Syndrome Treatment Market, By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Dry Eye Syndrome Treatment Market, By Region:

North America
- United States
- Mexico
- Canada
Europe
- France
- Germany
- United Kingdom
- Italy
- Spain
Asia-Pacific
- China
- India
- South Korea
- Japan
- Australia
South America
- Brazil
- Argentina
- Colombia
Middle East and Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Dry Eye Syndrome Treatment Market.

Available Customizations:

Global Dry Eye Syndrome Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Clinical Trial Analysis

5.1. Ongoing Clinical Trials
5.2. Completed Clinical Trials
5.3. Terminated Clinical Trials
5.4. Breakdown of Pipeline, By Development Phase
5.5. Breakdown of Pipeline, By Status
5.6. Breakdown of Pipeline, By Study Type
5.7. Breakdown of Pipeline, By Region
5.8. Clinical Trials Heat Map

6. Global Dry Eye Syndrome Treatment Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Indication (Evaporative Dry Eye Syndrome, Aqueous Deficient Dry Eye Syndrome)
- 6.2.2. By Product Type (Cyclosporine, Topical Corticosteroids, Artificial Tears, Punctal Plugs, Others)
- 6.2.3. By Dosage Form (Gels, Eye Solutions, Capsules & Tablets, Eye Drops, Ointments)
- 6.2.4. By Type (Prescription, Over The Counter)
- 6.2.5. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
- 6.2.6. By Region
- 6.2.7. By Company (2024)
6.3. Market Map
- 6.3.1. By Indication
- 6.3.2. By Product Type
- 6.3.3. By Dosage Form
- 6.3.4. By Type
- 6.3.5. By Distribution Channel
- 6.3.6. By Region

7. North America Dry Eye Syndrome Treatment Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Indication
- 7.2.2. By Product Type
- 7.2.3. By Dosage Form
- 7.2.4. By Type
- 7.2.5. By Distribution Channel
- 7.2.6. By Country
7.3. North America: Country Analysis
- 7.3.1. United States Dry Eye Syndrome Treatment Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Indication
    - 7.3.1.2.2. By Product Type
    - 7.3.1.2.3. By Dosage Form
    - 7.3.1.2.4. By Type
    - 7.3.1.2.5. By Distribution Channel
- 7.3.2. Canada Dry Eye Syndrome Treatment Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Indication
    - 7.3.2.2.2. By Product Type
    - 7.3.2.2.3. By Dosage Form
    - 7.3.2.2.4. By Type
    - 7.3.2.2.5. By Distribution Channel
- 7.3.3. Mexico Dry Eye Syndrome Treatment Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Indication
    - 7.3.3.2.2. By Product Type
    - 7.3.3.2.3. By Dosage Form
    - 7.3.3.2.4. By Type
    - 7.3.3.2.5. By Distribution Channel

8. Europe Dry Eye Syndrome Treatment Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Indication
- 8.2.2. By Product Type
- 8.2.3. By Dosage Form
- 8.2.4. By Type
- 8.2.5. By Distribution Channel
- 8.2.6. By Country
8.3. Europe: Country Analysis
- 8.3.1. France Dry Eye Syndrome Treatment Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Indication
    - 8.3.1.2.2. By Product Type
    - 8.3.1.2.3. By Dosage Form
    - 8.3.1.2.4. By Type
    - 8.3.1.2.5. By Distribution Channel
- 8.3.2. Germany Dry Eye Syndrome Treatment Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Indication
    - 8.3.2.2.2. By Product Type
    - 8.3.2.2.3. By Dosage Form
    - 8.3.2.2.4. By Type
    - 8.3.2.2.5. By Distribution Channel
- 8.3.3. United Kingdom Dry Eye Syndrome Treatment Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Indication
    - 8.3.3.2.2. By Product Type
    - 8.3.3.2.3. By Dosage Form
    - 8.3.3.2.4. By Type
    - 8.3.3.2.5. By Distribution Channel
- 8.3.4. Italy Dry Eye Syndrome Treatment Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Indication
    - 8.3.4.2.2. By Product Type
    - 8.3.4.2.3. By Dosage Form
    - 8.3.4.2.4. By Type
    - 8.3.4.2.5. By Distribution Channel
- 8.3.5. Spain Dry Eye Syndrome Treatment Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Indication
    - 8.3.5.2.2. By Product Type
    - 8.3.5.2.3. By Dosage Form
    - 8.3.5.2.4. By Type
    - 8.3.5.2.5. By Distribution Channel

9. Asia-Pacific Dry Eye Syndrome Treatment Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Indication
- 9.2.2. By Product Type
- 9.2.3. By Dosage Form
- 9.2.4. By Type
- 9.2.5. By Distribution Channel
- 9.2.6. By Country
9.3. Asia-Pacific: Country Analysis
- 9.3.1. China Dry Eye Syndrome Treatment Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Indication
    - 9.3.1.2.2. By Product Type
    - 9.3.1.2.3. By Dosage Form
    - 9.3.1.2.4. By Type
    - 9.3.1.2.5. By Distribution Channel
- 9.3.2. India Dry Eye Syndrome Treatment Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Indication
    - 9.3.2.2.2. By Product Type
    - 9.3.2.2.3. By Dosage Form
    - 9.3.2.2.4. By Type
    - 9.3.2.2.5. By Distribution Channel
- 9.3.3. Japan Dry Eye Syndrome Treatment Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Indication
    - 9.3.3.2.2. By Product Type
    - 9.3.3.2.3. By Dosage Form
    - 9.3.3.2.4. By Type
    - 9.3.3.2.5. By Distribution Channel
- 9.3.4. South Korea Dry Eye Syndrome Treatment Market Outlook
  - 9.3.4.1. Market Size & Forecast
    - 9.3.4.1.1. By Value
  - 9.3.4.2. Market Share & Forecast
    - 9.3.4.2.1. By Indication
    - 9.3.4.2.2. By Product Type
    - 9.3.4.2.3. By Dosage Form
    - 9.3.4.2.4. By Type
    - 9.3.4.2.5. By Distribution Channel
- 9.3.5. Australia Dry Eye Syndrome Treatment Market Outlook
  - 9.3.5.1. Market Size & Forecast
    - 9.3.5.1.1. By Value
  - 9.3.5.2. Market Share & Forecast
    - 9.3.5.2.1. By Indication
    - 9.3.5.2.2. By Product Type
    - 9.3.5.2.3. By Dosage Form
    - 9.3.5.2.4. By Type
    - 9.3.5.2.5. By Distribution Channel

10. South America Dry Eye Syndrome Treatment Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Indication
- 10.2.2. By Product Type
- 10.2.3. By Dosage Form
- 10.2.4. By Type
- 10.2.5. By Distribution Channel
- 10.2.6. By Country
10.3. South America: Country Analysis
- 10.3.1. Brazil Dry Eye Syndrome Treatment Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Indication
    - 10.3.1.2.2. By Product Type
    - 10.3.1.2.3. By Dosage Form
    - 10.3.1.2.4. By Type
    - 10.3.1.2.5. By Distribution Channel
- 10.3.2. Argentina Dry Eye Syndrome Treatment Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Indication
    - 10.3.2.2.2. By Product Type
    - 10.3.2.2.3. By Dosage Form
    - 10.3.2.2.4. By Type
    - 10.3.2.2.5. By Distribution Channel
- 10.3.3. Colombia Dry Eye Syndrome Treatment Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Indication
    - 10.3.3.2.2. By Product Type
    - 10.3.3.2.3. By Dosage Form
    - 10.3.3.2.4. By Type
    - 10.3.3.2.5. By Distribution Channel

11. Middle East and Africa Dry Eye Syndrome Treatment Market Outlook

11.1. Market Size & Forecast
- 11.1.1. By Value
11.2. Market Share & Forecast
- 11.2.1. By Indication
- 11.2.2. By Product Type
- 11.2.3. By Dosage Form
- 11.2.4. By Type
- 11.2.5. By Distribution Channel
- 11.2.6. By Country
11.3. MEA: Country Analysis
- 11.3.1. South Africa Dry Eye Syndrome Treatment Market Outlook
  - 11.3.1.1. Market Size & Forecast
    - 11.3.1.1.1. By Value
  - 11.3.1.2. Market Share & Forecast
    - 11.3.1.2.1. By Indication
    - 11.3.1.2.2. By Product Type
    - 11.3.1.2.3. By Dosage Form
    - 11.3.1.2.4. By Type
    - 11.3.1.2.5. By Distribution Channel
- 11.3.2. Saudi Arabia Dry Eye Syndrome Treatment Market Outlook
  - 11.3.2.1. Market Size & Forecast
    - 11.3.2.1.1. By Value
  - 11.3.2.2. Market Share & Forecast
    - 11.3.2.2.1. By Indication
    - 11.3.2.2.2. By Product Type
    - 11.3.2.2.3. By Dosage Form
    - 11.3.2.2.4. By Type
    - 11.3.2.2.5. By Distribution Channel
- 11.3.3. UAE Dry Eye Syndrome Treatment Market Outlook
  - 11.3.3.1. Market Size & Forecast
    - 11.3.3.1.1. By Value
  - 11.3.3.2. Market Share & Forecast
    - 11.3.3.2.1. By Indication
    - 11.3.3.2.2. By Product Type
    - 11.3.3.2.3. By Dosage Form
    - 11.3.3.2.4. By Type
    - 11.3.3.2.5. By Distribution Channel

12. Market Dynamics

12.1. Drivers
12.2. Challenges

13. Market Trends & Developments

13.1. Recent Developments
13.2. Mergers & Acquisitions
13.3. Product Launches

14. Global Dry Eye Syndrome Treatment Market: SWOT Analysis

15. Porters Five Forces Analysis

15.1. Competition in the Industry
15.2. Potential of New Entrants
15.3. Power of Suppliers
15.4. Power of Customers
15.5. Threat of Substitute Products/Services

16. Competitive Landscape

16.1. Johnson & Johnson Services, Inc.
- 16.1.1. Business Overview
- 16.1.2. Company Snapshot
- 16.1.3. Products & Services
- 16.1.4. Financials (As Reported)
- 16.1.5. Recent Developments
- 16.1.6. Key Personnel Details
- 16.1.7. SWOT Analysis
16.2. AbbVie Inc.
16.3. Bausch Health Companies Inc.
16.4. Novartis AG
16.5. Sun Pharmaceuticals Industries Limited
16.6. Santen Pharmaceutical Co., Ltd.
16.7. Otsuka Pharmaceutical Co., Ltd.
16.8. Oyster Point Pharma, Inc.
16.9. Alcon Inc.
16.10. GlaxoSmithKline plc